VIENNA, Austria, May 18, 2007 – Intercell AG (VSE,
“ICLL”) has been informed by its strategic partner
Merck & Co., Inc. on the results of a Phase I study involving
in total over 120 adult healthy volunteers comparing safety and
immunogenicity of different doses of the Staphylococcus aureus
vaccine.
The Staphylococcus aureus vaccine is based on a conserved protein
antigen discovered by Intercell’s Antigen Identification
Program (AIP®) and was licensed to Merck & Co., Inc. on an
exclusive world wide basis in 2003.
The data show that the vaccine is safe and generally well
tolerated. Immune responses were observed within several weeks
following vaccination and these immune responses persisted
throughout the course of the study.
“We are very pleased that the vaccine candidate, for which
the antigen was identified by our proprietary AIP® technology,
delivered promising clinical data, and look forward to its further
clinical development ”, states Gerd Zettlmeissl, CEO of
Intercell. “These data underline the high potential of our
AIP® technology for the identification of other bacterial
vaccine product candidates in?house or in collaboration with
leading vaccine companies”.
About Staphylococcus aureus and nosocomial infections
Hospital?acquired infections are one of the major causes of death
and serious illness worldwide,
resulting in an annual burden of more than USD 20 billion in the
developed world. In the United
States alone, about two million patients become infected annually
while receiving health care in
hospitals. The incidence of nosocomial infections is steadily
increasing due to medical
interventions and most notably due to the emergence of antibiotic
resistant bacteria circulating in
hospitals. Staphylococcus aureus is the most frequent cause of
hospital acquired infections. In
addition to bloodstream
'"/>Page: 1 2 3 Related medicine technology :1.
Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance2.
Pharmexa A/S (DK) - Long lasting immune response and survival to
RAS vaccine3.
Apollo develops needle-free topical vaccine4.
Pro-Pharmaceuticals to Present Abstract at the International
Society of Oncodevelopmental Biology and Medicine Conference5.
Data Available From Erbitux Phase III Study in First-Line Treatment
of Advanced Lung Cancer6.
Phase 3 Results for Dabigatran Etexilate, an Investigational Oral
Anticoagulant, Presented Today at the XXIst Congress of the
International Society on Thrombosis and Haemostasis7.
YM BioSciences Announces Secondary Efficacy and Safety Findings in
Randomized Phase IIB Aerolef Trial8.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis9.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone10.
Actemra (tocilizumab) Third Phase III Study Results Show
Significant Improvement in Symptoms of Patients with Rheumatoid
Arthritis11.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease